A real-world data-based safety profiling of monoclonal antibodies

Shihang Zeng

doi:10.1117/12.2668963

24 March 2023 A real-world data-based safety profiling of monoclonal antibodies

Shihang Zeng

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126114I (2023) https://doi.org/10.1117/12.2668963
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Mechanistically targeting cancer development, monoclonal antibodies (mAbs) had become a class of cancer therapy that possesses higher specificity and therefore less toxic comparing to conventional therapies. The current study summarized the development, category, properties and toxicity of mAbs, with focus on three typical mAbs (EGFR-TKIs, VEGF signaling pathway inhibitors, and PD-1/PD-L1 pathway inhibitors). Because of certain limitations of clinical trials (CTs), real-world studies (RWSs) have been employed to extend and complete the observation of usage of drug. In general, the efficacy and safety profile exhibited in CTs have been certified by RW data. Additionally, real-world studies included a much wider range of patients (elder patients, patients with uncommon mutations, and patients with other diseases), and the results of which indicated that mAbs also exhibited desirable effectiveness and mild adverse events (AEs) in all subgroups. Notably, VEGFR-TKIs-induced thyroid dysfunction is a little more common among older patients, and PD-1/PD-L1 pathway inhibitors have the risk of causing relevant AEs among patients with special conditions, while all of the treatment-associated AEs are tolerable and manageable.

Citation Download Citation

Shihang Zeng "A real-world data-based safety profiling of monoclonal antibodies", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126114I (24 March 2023); https://doi.org/10.1117/12.2668963

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available